Park Avenue Securities LLC Raises Stake in Pfizer Inc. $PFE

Park Avenue Securities LLC grew its stake in Pfizer Inc. (NYSE:PFE) by 25.4% in the third quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund owned 196,932 shares of the biopharmaceutical company’s stock after acquiring an additional 39,882 shares during the quarter. Park Avenue Securities LLC’s holdings in Pfizer were worth $5,018,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds have also recently modified their holdings of the company. Brighton Jones LLC raised its position in shares of Pfizer by 1,282.4% during the 4th quarter. Brighton Jones LLC now owns 666,318 shares of the biopharmaceutical company’s stock valued at $17,677,000 after buying an additional 618,117 shares during the period. Revolve Wealth Partners LLC increased its stake in Pfizer by 12.5% during the fourth quarter. Revolve Wealth Partners LLC now owns 18,766 shares of the biopharmaceutical company’s stock worth $498,000 after acquiring an additional 2,087 shares during the last quarter. Great Lakes Advisors LLC raised its position in Pfizer by 381.0% in the first quarter. Great Lakes Advisors LLC now owns 80,383 shares of the biopharmaceutical company’s stock valued at $2,037,000 after purchasing an additional 63,670 shares during the period. MBB Public Markets I LLC acquired a new position in shares of Pfizer in the 1st quarter valued at $307,000. Finally, SCS Capital Management LLC purchased a new position in shares of Pfizer during the 1st quarter worth $778,000. Institutional investors and hedge funds own 68.36% of the company’s stock.

More Pfizer News

Here are the key news stories impacting Pfizer this week:

• Positive Sentiment: Positive topline Phase 3 EV‑304 (KEYNOTE‑B15) results: Pfizer and Astellas reported the PADCEV (enfortumab vedotin) + Keytruda combo met its primary goals in bladder cancer, which could expand oncology revenue and provide a meaningful new commercial opportunity. Pfizer, Astellas Report Positive Phase 3 Trial Results for PADCEV Combination in Bladder Cancer Treatment
• Positive Sentiment: GLP‑1 / turnaround narrative: Coverage and commentary highlight Pfizer’s moves into obesity/GLP‑1 areas (licensing deals and pipeline focus) as a potential multi‑year growth catalyst that investors are valuing alongside legacy product cash flows. This Could Be Key to Pfizer’s Turnaround in 2026
• Neutral Sentiment: Observational RSV maternal vaccine study update: Pfizer provided results/updates on a Scottish observational study — useful for longer‑term vaccine positioning but unlikely to move the stock materially near term. Pfizer’s Scottish RSV Maternal Vaccine Study: What Investors Should Watch
• Neutral Sentiment: Exchange requests clarification from Pfizer Limited on Q2 FY2025 financials — procedural item for the regional listing that bears monitoring but is localized and not an immediate U.S. earnings issue. Exchange Seeks Clarification from Pfizer Limited on Q2 FY2025 Financial Results
• Negative Sentiment: Litigation timeline set: A trial date was scheduled in the MDL over Depo‑Provera claims for Dec. 2026 (2,100+ plaintiffs), adding legal overhang and potential settlement/judgment risk for investors to watch. Trial Date Has Been Set in MDL against Pfizer for Depo-Provera Overseen by Levin Papantonio
• Negative Sentiment: Analyst caution / valuation concerns: UBS initiated a Hold citing patent cliff risks and pipeline uncertainty that offset obesity upside — a rating that can pressure sentiment if echoed by other shops. Patent Cliff Overhang and Uncertain Pipeline Offset Obesity Upside, Justifying Hold on Fairly Valued Pfizer Shares
• Negative Sentiment: Guidance / margin concerns highlighted by commentary: Analysis and notes (including a Seeking Alpha piece) point to 2026 guidance that implies continued margin and growth pressure — a reminder that near‑term earnings drivers remain mixed. Pfizer: 2026 Guidance Points To Continued Margin And Growth Pressure

Pfizer Price Performance

Shares of PFE opened at $25.29 on Friday. The company has a market cap of $143.76 billion, a P/E ratio of 14.70 and a beta of 0.47. Pfizer Inc. has a fifty-two week low of $20.92 and a fifty-two week high of $27.69. The company has a quick ratio of 0.97, a current ratio of 1.28 and a debt-to-equity ratio of 0.62. The firm’s 50 day moving average price is $25.25 and its 200 day moving average price is $24.94.

Pfizer (NYSE:PFE) last posted its quarterly earnings results on Tuesday, November 4th. The biopharmaceutical company reported $0.87 EPS for the quarter, topping the consensus estimate of $0.79 by $0.08. The business had revenue of $16.65 billion during the quarter, compared to the consensus estimate of $16.94 billion. Pfizer had a net margin of 15.65% and a return on equity of 20.17%. Pfizer has set its FY 2025 guidance at 3.000-3.150 EPS. On average, research analysts forecast that Pfizer Inc. will post 2.95 earnings per share for the current fiscal year.

Pfizer Dividend Announcement

The business also recently declared a quarterly dividend, which will be paid on Friday, March 6th. Shareholders of record on Friday, January 23rd will be given a $0.43 dividend. The ex-dividend date of this dividend is Friday, January 23rd. This represents a $1.72 dividend on an annualized basis and a yield of 6.8%. Pfizer’s dividend payout ratio (DPR) is currently 100.00%.

Analyst Ratings Changes

A number of research firms have commented on PFE. Guggenheim reaffirmed a “buy” rating on shares of Pfizer in a research report on Wednesday, December 17th. Wolfe Research set a $24.00 price target on shares of Pfizer and gave the company an “underperform” rating in a research note on Wednesday, December 17th. Sanford C. Bernstein reaffirmed a “market perform” rating and set a $30.00 price objective on shares of Pfizer in a research report on Friday, October 31st. Cowen reiterated a “hold” rating on shares of Pfizer in a report on Tuesday, December 30th. Finally, HSBC restated a “buy” rating and set a $29.00 price target on shares of Pfizer in a research note on Wednesday, December 10th. Two investment analysts have rated the stock with a Strong Buy rating, four have given a Buy rating, thirteen have assigned a Hold rating and one has given a Sell rating to the stock. According to MarketBeat, the company has an average rating of “Hold” and an average target price of $27.88.

Pfizer Company Profile

Pfizer Inc (NYSE: PFE) is a multinational biopharmaceutical company headquartered in New York City. Founded in 1849 by Charles Pfizer and Charles Erhart, the company researches, develops, manufactures and commercializes a broad range of medicines and vaccines for human health. Its activities span discovery research, clinical development, regulatory affairs, manufacturing and global commercial distribution across multiple therapeutic areas.

Pfizer’s portfolio and pipeline cover oncology, immunology, cardiology, endocrinology, rare diseases, hospital acute care and anti-infectives, along with a substantial vaccine business.